相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
Georgina Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Matteo S. Carlino et al.
EUROPEAN JOURNAL OF CANCER (2018)
4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Razvan Cristescu et al.
SCIENCE (2018)
Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017
Selma Ugurel et al.
EUROPEAN JOURNAL OF CANCER (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
Georgina V. Long et al.
LANCET ONCOLOGY (2016)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
J. D. Wolchok et al.
ANNALS OF ONCOLOGY (2013)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
分享论文
